Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C): assessor masked, multicentre, randomised controlled trial.

Name: Kaimen Rigor review — Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C): assessor masked, multicentre, randomised controlled trial.
Item: Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C): assessor masked, multicentre, randomised controlled trial.
Rating: 100
Author: Alpha1

Haun MW, Tönnies J, Hartmann M, Wildenauer A, Wensing M, Szecsenyi J, Feißt M, Pohl M, Vomhof M, Icks A, Friederich HC

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 2 high issues for “Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C): assessor masked, multicentre, randomised controlled trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C): assessor masked, multicentre, randomised controlled trial.

Haun MW, Tönnies J, Hartmann M, Wildenauer A, Wensing M, Szecsenyi J, Feißt M, Pohl M, Vomhof M, Icks A, Friederich HC

Read full text (PMC)

DOI

10.1136/bmj-2024-079921

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/b00c65ba-24c6-4314-8824-00305329f12c" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/b00c65ba-24c6-4314-8824-00305329f12c/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 2 high issues for “Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C): assessor masked, multicentre, randomised controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

6286fac1724ac23f300dadd10c71010837971520ce5fecf4d908857c02f3c8aa

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C): assessor masked, multicentre, randomised controlled trial.

Haun MW, Tönnies J, Hartmann M, Wildenauer A, Wensing M, Szecsenyi J, Feißt M, Pohl M, Vomhof M, Icks A, Friederich HC

Paper source

Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C): assessor masked, multicentre, randomised controlled trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

CitationsUnresolved reference ×3−0.75★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 83 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary outcome is the PHQ-ADS score, a patient-reported symptom scale, which is a surrogate for clinical benefit. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD or dose-exposure) nor cite validated evidence linking changes in PHQ-ADS to hard clinical outcomes. The minimal clinically important difference is mentioned but not validated as a surrogate for long-term outcomes.
“The primary outcome was the absolute change in the mean severity of depressive and anxiety symptoms measured using the patient health questionnaire anxiety and depression scale (PHQ-ADS) at six months”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect size is small (Cohen's d = 0.21 at 6 months) and the adjusted mean difference (-2.4 points) is below the minimal clinically important difference of 3-5 points. The paper acknowledges this but argues population-level impact, yet the effect is not anchored to a clinically meaningful threshold for individual patients.
“The difference in the change of 2.3 points was lower than that of the minimal clinically important difference in the PHQ-ADS score (3-5 point change).”
Find in source

Findings by category

01ArithmeticNone found 302OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 105AvailabilityBroken references and links 06Copyedit7 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported randomised controlled trial with rigorous design, clear ethical approvals, and appropriate statistical methods. Minor reporting gaps include lack of explicit Declaration of Helsinki mention and a few copyedit issues, but these do not undermine the scientific integrity.

Both reviewers classified the study as interventional; no divergence. The evaluation covered the full text, with statistics verification limited to 6 recomputable tests (all consistent) and citation check finding 3 references not found in registry (potential fabrication signals).

Numerical inconsistencies

None found

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Checked — nothing surfaced.

Recomputed 6 tests: 6 consistent, 0 inconsistent; 2 recomputed directly from the reported test statistics, 4 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites a systematic review of co-located care and notes the need for more rigorous RCTs, and mentions prior pilot work (PROVIDE-B). The rationale links the gap in scalable integrated mental health video consultations to the study objective. Limitations of prior research (e.g., conducted in highly regulated environments) are explicitly acknowledged.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited, a logical rationale, and addresses limitations of prior research.

Evidence

“In 2020, the results from a systematic review of 15 studies showed that co-located specialty care was associated with mental health benefits, and concluded that more rigorous randomised controlled trials are needed.”

Introduction ¶3Find in source

“The aim of this assessor masked randomised controlled trial was to investigate the effectiveness of this new mental health service model for treating people with depression or anxiety, or both, in primary care settings.”

Introduction ¶4Find in source

“The limited number of published randomised controlled trials to date were conducted in highly regulated environments, such as the US Veterans Health Care Administration, or involved patients from inpatient facilities.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited, a logical rationale, and addresses limitations of prior research.

Evidence

Introduction ¶3Find in source

Introduction ¶4Find in source

“The potential scalability of these models to primary care settings, particularly in countries where smaller, single handed, or rural and remote practices dominate, remains uncertain.”

Introduction ¶3Find in source

Randomization used a secure web-based system with computer-generated sequence, stratified by centre and severity, with random permuted blocks. Blinding of outcome assessors and data analysts is described, with a note on unintentional unmasking. Sample size calculation is provided with effect size, alpha, power, and dropout adjustment. Inclusion/exclusion criteria are detailed. Outlier handling is addressed through graphical evaluation of assumptions and multiple imputation for missing data. Controls are appropriate (usual care). Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“Eligible participants were then randomly assigned (1:1) to the intervention or control group via a secure web based randomisation system (Randomiser V.2.0.2) operated by a data manager who was not involved in patient recruitment, centrally at the Institute of Medical Biometry, Heidelberg University.”

MethodsFind in source

“While the patients, GPs, and mental health specialists were aware of the intervention assignment after allocation, the data analysts were masked to the allocation.”

MethodsFind in source

“To detect the minimal clinically important difference in the PHQ-ADS score of 3 points (SD 9 points) with a two sided 5% significance level and a power of 80%, a sample size of 160 patients per group was necessary.”

MethodsFind in source

PASSReviewer 2· 90% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

MethodsFind in source

“While the patients, GPs, and mental health specialists were aware of the intervention assignment after allocation, the data analysts were masked to the allocation.”

MethodsFind in source

Sex is reported (63% female), age (mean 45, SD 14), and health status (chronic physical disease, symptom severity). Demographics include marital status, education, employment, income, and psychiatric history. Since both sexes are enrolled, sex_justified is not applicable. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and health status.

Evidence

“Mean age was 45 years (standard deviation (SD) 14), 63% of the participants were female”

AbstractFind in source

“A total of 220 (59%) participants had at least one chronic physical disease.”

ResultsFind in source

paraphrase[Table 1]

“Marital status, n (%): Single 58 (31) 49 (27) 107 (29)”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and health status.

Evidence

“Of the 376 participants, 238 (63%) participants were female. The mean age was 45 years (SD 14; range 18-81).”

ResultsFind in source

“A total of 220 (59%) participants had at least one chronic physical disease.”

ResultsFind in source

“Table 1 Baseline characteristics of the intention-to-treat population”

Table 1Find in source

The trial was approved by the Medical Faculty of the University of Heidelberg Ethics Committee (S-923/2019) on 7 January 2020. All participants provided written informed consent. Regulatory compliance is implied through adherence to CONSORT and ethical standards, though not explicitly naming a framework like the Declaration of Helsinki.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and informed consent are clearly documented.

Evidence

“The trial protocol was approved by the Medical Faculty of the University of Heidelberg Ethics Committee (S-923/2019) on 7 January 2020.”

EthicsFind in source

“All participants provided written informed consent to participate in this trial.”

EthicsFind in source

“We reported the PROVIDE-C trial in accordance with the CONSORT 2010 statement.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approval and informed consent are clearly documented.

Evidence

“The trial protocol was approved by the Medical Faculty of the University of Heidelberg Ethics Committee (S-923/2019) on 7 January 2020.”

EthicsFind in source

“All participants provided written informed consent to participate in this trial.”

EthicsFind in source

“We reported the PROVIDE-C trial in accordance with the CONSORT 2010 statement.”

MethodsFind in source

The intervention is described in detail, including the videoconferencing platform (arztkonsultation ak GmbH) and the intervention manual. The statistical software (R 4.4.0) is identified. No antibodies, cell lines, or organisms are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (PROVIDE intervention) and key software are adequately identified.

Evidence

“The intervention was delivered through individual, synchronous one-to-one video consultations conducted via an encrypted, web based videoconferencing platform on a subscription basis (arztkonsultation ak GmbH, Schwerin, Germany, https://arztkonsultation.de ).”

MethodsFind in source

“The analyses were performed using R 4.4.0 or higher.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (video consultation platform) and software are identified, and no bench reagents are used.

Evidence

MethodsFind in source

“The analyses were performed using R 4.4.0 or higher.”

Statistical analysisFind in source

“via a secure web based randomisation system (Randomiser V.2.0.2)”

MethodsFind in source

The primary analysis uses a mixed linear model with multiple imputation, and assumptions are graphically evaluated. Exact p-values are reported (e.g., P=0.02). Effect sizes with 95% CIs are provided. Statistical software is identified. Data presentation includes per-group n and SDs. Mathematical plausibility checks were not possible for all values due to model-based estimates, but no obvious errors were found.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-reported, with exact p-values and effect sizes with confidence intervals.

Evidence

“We analysed the primary outcome with a mixed linear model, where a random intercept accounted for the primary care practice to which the patient belonged.”

Statistical analysisFind in source

“adjusted mean change difference −2.4 points (−4.5 to −0.4), P=0.02”

ResultsFind in source

“The effect size (Cohen’s d) was 0.21 (95% CI 0.03 to 0.39).”

ResultsFind in source

PASSReviewer 2· 85% conf

Statistical methods are appropriate and well reported, with exact p-values and effect sizes with confidence intervals.

Evidence

“We analysed the primary outcome with a mixed linear model, where a random intercept accounted for the primary care practice to which the patient belonged.”

Statistical analysisFind in source

“adjusted mean change difference −2.4 points (−4.5 to −0.4), P=0.02”

ResultsFind in source

“The effect size (Cohen’s d) was 0.21 (95% CI 0.03 to 0.39).”

ResultsFind in source

The data availability statement describes a managed-access process: deidentified participant data will be available nine months after publication to investigators whose proposed use is approved by an independent review committee. This is adequate for patient-level data. No public repository deposit or accession numbers are applicable for identifiable patient data. Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement is concrete, with a managed-access procedure for deidentified participant data.

Evidence

“For individual participant data meta-analysis, beginning nine months following article publication, deidentified participant data that underlie the results reported in this article (text, tables, figures, and appendices) and a data dictionary will be available to investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.”

Data availabilityFind in source

PASSReviewer 2· 85% conf

Data availability statement is concrete, with a managed-access procedure for deidentified participant data.

Evidence

Data availabilityFind in source

Trial registration is provided (NCT04316572). CONSORT 2010 is referenced. All pre-specified outcomes are reported, including non-significant ones. Limitations are thoroughly discussed. Conclusions are proportional to the evidence, acknowledging the small effect size. Funding and competing interests are declared.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is registered, follows CONSORT, reports all outcomes, discusses limitations, and provides funding/COI statements.

Evidence

“Trial registration ClinicalTrials.gov NCT04316572 (https://clinicaltrials.gov/ct2/show/NCT04316572) .”

AbstractFind in source

“We reported the PROVIDE-C trial in accordance with the CONSORT 2010 statement.”

MethodsFind in source

“This study has several limitations. Selection bias is a pressing issue in practice based clinical research.”

DiscussionFind in source

PASSReviewer 2· 90% conf

The trial is registered, follows CONSORT, reports all outcomes, discusses limitations, and provides funding and COI statements.

Evidence

“Trial registration ClinicalTrials.gov NCT04316572 (https://clinicaltrials.gov/ct2/show/NCT04316572) .”

AbstractFind in source

“We reported the PROVIDE-C trial in accordance with the CONSORT 2010 statement.”

MethodsFind in source

“Funding: This trial was funded by a grant from the German Federal Ministry of Education and Research (BMBF) (grant no. 01GY16129).”

FundingFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 72 references by DOI: 65 verified — 3 DOI unresolved, 4 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

7 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 7 minor suggestions below.

7 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported; an informed reader should weigh the minor reporting gaps (explicit regulatory framework, rounding inconsistencies) and the three unresolved references as potential concerns, but none warrant immediate erratum. The statistics are consistent for the subset checked, and the trial is registered and follows CONSORT.

1.
HIGHreporting
Verify or correct the three references not found in any registry: 'World mental health report: transforming mental health for all' (DOI 10.1016/s0140-6736(18), 'Primary Care Mental Health' (DOI 10.1016/s0140-6736(07), and 'On‐site mental health workers delivering psychological therapy and psychosocial interventions to patients in primary care' (DOI 10.1002/14651858.cd000532.pub2/abstract).
References that cannot be located in Crossref/OpenAlex may be fabricated or contain incorrect DOIs, which is a serious integrity concern.
2.
HIGHethics
In the Ethics statements, explicitly name the regulatory framework (e.g., Declaration of Helsinki) and whether the trial followed ICH-GCP or equivalent.
One reviewer flagged regulatory compliance as inadequate because the framework is not explicitly named; adding this strengthens the ethics reporting.
3.
MEDIUMreporting
Standardize the primary outcome estimate to one decimal place across text and Table 2 (text: −2.4; table: −2.43) and clarify the footnote on effect sizes in Table 2.
Inconsistent rounding and ambiguous footnotes can confuse readers and are easily fixed.
4.
MEDIUMcopyedit
Fix the sentence fragment in the Discussion, Strengths and weaknesses: 'The trial has substantial strengths. The sample predominantly included female participants...' by merging or rephrasing.
Grammar issues detract from the paper's professionalism.
5.
MEDIUMcopyedit
Rephrase the responder analysis sentence in Methods, Statistical analysis for clarity: 'We decided to perform a responder analysis, comparing the proportion of participants within each study arm who had a change at least as large as the minimal clinically important difference, as part of the secondary analyses.'
The original sentence is long and could be misread.
6.
MEDIUMcopyedit
Add 'points' to the 12-month effect in the Abstract: '−2.9 points (−5.0 to −0.7)' and ensure consistent dash usage.
Clarifies the unit and improves formatting consistency.
7.
MEDIUMcopyedit
Check the footnote symbol placement in Table 3, row '12 item short form survey' (1.13 (−0.83 to 3.09)‡).
Misplaced footnote symbols can mislead readers.
8.
MEDIUMdata code
Consider providing the statistical analysis code in a public repository or as a supplementary file, even though data are controlled access.
Sharing code enhances reproducibility and is a common reviewer request.
9.
MEDIUMreporting
Report the number of participants with missing data for each secondary outcome at each time point in the tables.
Transparency about missing data strengthens the reporting of secondary analyses.
10.
MEDIUMreporting
Discuss the potential impact of the high rate of unintentional unmasking (20%) on the primary outcome in the limitations section.
Unmasking can bias outcome assessment; addressing it directly is important for interpretation.
11.
LOWreporting
Provide a link to the published protocol or statistical analysis plan in the data availability statement.
Enhances transparency and allows independent verification.
12.
LOWreporting
Consider reporting the intraclass correlation coefficient for the primary outcome in the abstract.
Provides additional context for the cluster-randomized design.

Full text (80,906 chars · analyzed ~93%, head + tail)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C): assessor masked, multicentre, randomised controlled trial.

Haun MW, Tönnies J, Hartmann M, Wildenauer A, Wensing M, Szecsenyi J, Feißt M, Pohl M, Vomhof M, Icks A, Friederich HC

Read full text (PMC)

DOI

10.1136/bmj-2024-079921

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/b00c65ba-24c6-4314-8824-00305329f12c" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/b00c65ba-24c6-4314-8824-00305329f12c/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 2 high issues for “Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C): assessor masked, multicentre, randomised controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

6286fac1724ac23f300dadd10c71010837971520ce5fecf4d908857c02f3c8aa

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

CitationsUnresolved reference ×3−0.75★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 83 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary outcome is the PHQ-ADS score, a patient-reported symptom scale, which is a surrogate for clinical benefit. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD or dose-exposure) nor cite validated evidence linking changes in PHQ-ADS to hard clinical outcomes. The minimal clinically important difference is mentioned but not validated as a surrogate for long-term outcomes.
“The primary outcome was the absolute change in the mean severity of depressive and anxiety symptoms measured using the patient health questionnaire anxiety and depression scale (PHQ-ADS) at six months”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect size is small (Cohen's d = 0.21 at 6 months) and the adjusted mean difference (-2.4 points) is below the minimal clinically important difference of 3-5 points. The paper acknowledges this but argues population-level impact, yet the effect is not anchored to a clinically meaningful threshold for individual patients.
“The difference in the change of 2.3 points was lower than that of the minimal clinically important difference in the PHQ-ADS score (3-5 point change).”
Find in source

Findings by category

01ArithmeticNone found 302OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 105AvailabilityBroken references and links 06Copyedit7 minor suggestions

Numerical inconsistencies

None found

Checked — nothing surfaced.

Recomputed 6 tests: 6 consistent, 0 inconsistent; 2 recomputed directly from the reported test statistics, 4 via agent-written checks.

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited, a logical rationale, and addresses limitations of prior research.

Evidence

Introduction ¶3Find in source

Introduction ¶4Find in source

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited, a logical rationale, and addresses limitations of prior research.

Evidence

Introduction ¶3Find in source

Introduction ¶4Find in source

“The potential scalability of these models to primary care settings, particularly in countries where smaller, single handed, or rural and remote practices dominate, remains uncertain.”

Introduction ¶3Find in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

MethodsFind in source

“While the patients, GPs, and mental health specialists were aware of the intervention assignment after allocation, the data analysts were masked to the allocation.”

MethodsFind in source

PASSReviewer 2· 90% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

MethodsFind in source

“While the patients, GPs, and mental health specialists were aware of the intervention assignment after allocation, the data analysts were masked to the allocation.”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and health status.

Evidence

“Mean age was 45 years (standard deviation (SD) 14), 63% of the participants were female”

AbstractFind in source

“A total of 220 (59%) participants had at least one chronic physical disease.”

ResultsFind in source

paraphrase[Table 1]

“Marital status, n (%): Single 58 (31) 49 (27) 107 (29)”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and health status.

Evidence

“Of the 376 participants, 238 (63%) participants were female. The mean age was 45 years (SD 14; range 18-81).”

ResultsFind in source

“A total of 220 (59%) participants had at least one chronic physical disease.”

ResultsFind in source

“Table 1 Baseline characteristics of the intention-to-treat population”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and informed consent are clearly documented.

Evidence

“The trial protocol was approved by the Medical Faculty of the University of Heidelberg Ethics Committee (S-923/2019) on 7 January 2020.”

EthicsFind in source

“All participants provided written informed consent to participate in this trial.”

EthicsFind in source

“We reported the PROVIDE-C trial in accordance with the CONSORT 2010 statement.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approval and informed consent are clearly documented.

Evidence

“The trial protocol was approved by the Medical Faculty of the University of Heidelberg Ethics Committee (S-923/2019) on 7 January 2020.”

EthicsFind in source

“All participants provided written informed consent to participate in this trial.”

EthicsFind in source

“We reported the PROVIDE-C trial in accordance with the CONSORT 2010 statement.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (PROVIDE intervention) and key software are adequately identified.

Evidence

MethodsFind in source

“The analyses were performed using R 4.4.0 or higher.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (video consultation platform) and software are identified, and no bench reagents are used.

Evidence

MethodsFind in source

“The analyses were performed using R 4.4.0 or higher.”

Statistical analysisFind in source

“via a secure web based randomisation system (Randomiser V.2.0.2)”

MethodsFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-reported, with exact p-values and effect sizes with confidence intervals.

Evidence

“We analysed the primary outcome with a mixed linear model, where a random intercept accounted for the primary care practice to which the patient belonged.”

Statistical analysisFind in source

“adjusted mean change difference −2.4 points (−4.5 to −0.4), P=0.02”

ResultsFind in source

“The effect size (Cohen’s d) was 0.21 (95% CI 0.03 to 0.39).”

ResultsFind in source

PASSReviewer 2· 85% conf

Statistical methods are appropriate and well reported, with exact p-values and effect sizes with confidence intervals.

Evidence

“We analysed the primary outcome with a mixed linear model, where a random intercept accounted for the primary care practice to which the patient belonged.”

Statistical analysisFind in source

“adjusted mean change difference −2.4 points (−4.5 to −0.4), P=0.02”

ResultsFind in source

“The effect size (Cohen’s d) was 0.21 (95% CI 0.03 to 0.39).”

ResultsFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement is concrete, with a managed-access procedure for deidentified participant data.

Evidence

Data availabilityFind in source

PASSReviewer 2· 85% conf

Data availability statement is concrete, with a managed-access procedure for deidentified participant data.

Evidence

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is registered, follows CONSORT, reports all outcomes, discusses limitations, and provides funding/COI statements.

Evidence

“Trial registration ClinicalTrials.gov NCT04316572 (https://clinicaltrials.gov/ct2/show/NCT04316572) .”

AbstractFind in source

“We reported the PROVIDE-C trial in accordance with the CONSORT 2010 statement.”

MethodsFind in source

“This study has several limitations. Selection bias is a pressing issue in practice based clinical research.”

DiscussionFind in source

PASSReviewer 2· 90% conf

The trial is registered, follows CONSORT, reports all outcomes, discusses limitations, and provides funding and COI statements.

Evidence

“Trial registration ClinicalTrials.gov NCT04316572 (https://clinicaltrials.gov/ct2/show/NCT04316572) .”

AbstractFind in source

“We reported the PROVIDE-C trial in accordance with the CONSORT 2010 statement.”

MethodsFind in source

“Funding: This trial was funded by a grant from the German Federal Ministry of Education and Research (BMBF) (grant no. 01GY16129).”

FundingFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 72 references by DOI: 65 verified — 3 DOI unresolved, 4 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

7 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 7 minor suggestions below.

7 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHreporting
Verify or correct the three references not found in any registry: 'World mental health report: transforming mental health for all' (DOI 10.1016/s0140-6736(18), 'Primary Care Mental Health' (DOI 10.1016/s0140-6736(07), and 'On‐site mental health workers delivering psychological therapy and psychosocial interventions to patients in primary care' (DOI 10.1002/14651858.cd000532.pub2/abstract).
References that cannot be located in Crossref/OpenAlex may be fabricated or contain incorrect DOIs, which is a serious integrity concern.
2.
HIGHethics
In the Ethics statements, explicitly name the regulatory framework (e.g., Declaration of Helsinki) and whether the trial followed ICH-GCP or equivalent.
One reviewer flagged regulatory compliance as inadequate because the framework is not explicitly named; adding this strengthens the ethics reporting.
3.
MEDIUMreporting
Standardize the primary outcome estimate to one decimal place across text and Table 2 (text: −2.4; table: −2.43) and clarify the footnote on effect sizes in Table 2.
Inconsistent rounding and ambiguous footnotes can confuse readers and are easily fixed.
4.
MEDIUMcopyedit
Fix the sentence fragment in the Discussion, Strengths and weaknesses: 'The trial has substantial strengths. The sample predominantly included female participants...' by merging or rephrasing.
Grammar issues detract from the paper's professionalism.
5.
MEDIUMcopyedit
Rephrase the responder analysis sentence in Methods, Statistical analysis for clarity: 'We decided to perform a responder analysis, comparing the proportion of participants within each study arm who had a change at least as large as the minimal clinically important difference, as part of the secondary analyses.'
The original sentence is long and could be misread.
6.
MEDIUMcopyedit
Add 'points' to the 12-month effect in the Abstract: '−2.9 points (−5.0 to −0.7)' and ensure consistent dash usage.
Clarifies the unit and improves formatting consistency.
7.
MEDIUMcopyedit
Check the footnote symbol placement in Table 3, row '12 item short form survey' (1.13 (−0.83 to 3.09)‡).
Misplaced footnote symbols can mislead readers.
8.
MEDIUMdata code
Consider providing the statistical analysis code in a public repository or as a supplementary file, even though data are controlled access.
Sharing code enhances reproducibility and is a common reviewer request.
9.
MEDIUMreporting
Report the number of participants with missing data for each secondary outcome at each time point in the tables.
Transparency about missing data strengthens the reporting of secondary analyses.
10.
MEDIUMreporting
Discuss the potential impact of the high rate of unintentional unmasking (20%) on the primary outcome in the limitations section.
Unmasking can bias outcome assessment; addressing it directly is important for interpretation.
11.
LOWreporting
Provide a link to the published protocol or statistical analysis plan in the data availability statement.
Enhances transparency and allows independent verification.
12.
LOWreporting
Consider reporting the intraclass correlation coefficient for the primary outcome in the abstract.
Provides additional context for the cluster-randomized design.

Full text (80,906 chars · analyzed ~93%, head + tail)Analyzed: Aug 16, 2026